ABSTRACT
Subvalvular myectomy has a reported success of more than 90% with a mortality rate of less than 2%, but this therapy is not applicable to every patient. Transcatheter ablation of septal hypertrophy has been performed since 1994 as a reasonable option for obstructive HCM patients. An increasing number of reports claim efficacy comparable to that of the surgical approach (3).
